We report a case of relapsed high-risk non-metastatic medulloblastoma in a 14-year-old boy, which was treated with intensity-modulated radiotherapy (IMRT) and temozolomide (TMZ). At the age of 11, the patient underwent an MRI-confirmed incomplete resection of a fourth-ventricle medulloblastoma, followed by conventional chemotherapy, craniospinal irradiation (55.8 Gy, 1.8 Gy/fraction) and then myeloablative chemotherapy followed by peripheral blood progenitor cell rescue. After 18 months of complete remission following the completion of chemotherapy, MRI showed a 2.5-cm mass in the olfactory notch. The patient underwent IMRT (45 Gy, 1.8 Gy/fraction) with concomitant administration of TMZ (180 mg/m2, 5 days every 21 days), which was well tolerated. After 5 cycles of TMZ, MRI showed complete remission with no evidence of the mass. TMZ was continued for another 5 cycles and then stopped. At 14 months from the completion of IMRT, a new MRI scan showed multiple nodular relapses around the fourth ventricle and the patient is currently treated with oral etoposide.
RutkowskiS., von BuerenA., von HoffK., HartmannW., ShalabyT., DeinleinF., Warmuth-MetzM., SoerensenN., EmserA., BodeU., MittlerU., UrbanC., BeneschM., KortmannR.D., SchlegelP.G., KuehlJ., PietschT., GrotzerM.: Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: Results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res, 13: 2651–2657, 2007.
2.
RutkowskiS., GerberN.U., von HoffK., GnekowA., BodeU., GrafN., EmserA., PietschT., WolffJ.E., KortmannR.D., KuehlJ.: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med, 352: 978–986, 2005.
3.
PackerR.J., RoodB.R., MacDonaldT.J.: Medulloblastoma: Present concepts of stratification into risk groups. Pediatr Neurosurg, 39: 60–67, 2003.
4.
ZeltzerP.M., BoyettJ.M., FinlayJ.L., AlbrightA.L., RorkeL.B., MilsteinJ.M., AllenJ.C., StevensK.R., StanleyP., LiH., WisoffJ.H., GeyerJ.R., McGuire-CullenP., StehbensJ.A., ShurinS.B., PackerR.J.: Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol, 17: 832–845, 1999.
5.
OkadaS., HongoT., SakaguchiK., SuzukiK., NishizawaS., OhzekiT.: Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma. Childs Nerv Syst, 23: 407–413, 2007.
6.
KadotaR.P., MahoneyD.H., DoyleJ., DuerstR., FriedmanH., HolmesE., KunL., ZhouT., PollackI.F.: Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer, 51: 675–678, 2008.
7.
PatriceS.J., TarbellN.J., GoumnerovaL.C., ShrieveD.C., BlackP.M., LoefflerJ.S.: Results of radiosurgery in the management of recurrent and residual medulloblastoma. Pediatr Neurosurg, 22: 197–203, 1995.
8.
SaranF., BaumertB.G., CreakA.L., WarringtonA.P., AshleyS., TraishD., BradaM.: Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET. Pediatr Blood Cancer, 50: 554–560, 2008.
9.
DurandoX., ThivatE., GilliotO., IrthumB., VerrelleP., VincentC., BayJ.O.: Temozolomide treatment of an adult with a relapsing medulloblastoma. Cancer Invest, 25: 470–475, 2007.
10.
PoelenJ., BernsenH.J., PrickM.J.: Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg, 107: 51–54, 2007.
11.
NicholsonH.S., KretschmarC.S., KrailoM., BernsteinM., KadotaR., FortD., FriedmanH., HarrisM.B., Tedeschi-BlokN., MazewskiC., SatoJ., ReamanG.H.: Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer, 110: 1542–1550, 2007.
12.
SterbaJ., PavelkaZ., SlampaP.: Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma, 49: 117–120, 2002.
13.
BroniscerA., GururanganS., MacDonaldT.J., GoldmanS., PackerR.J., StewartC.F., DanksM.K., FriedmanH.S., PoussaintT.Y., KunL.E., BoyettJ.M., GajjarA.: Phase I trial of single-dose temozolomide and continuous administration of O6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res, 15: 6712–6718, 2007.
14.
WedgeS.R., PorteousJ.K., GlaserM.G., MarcusK., NewlandsE.S.: In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs, 8: 92–97, 1997.
15.
ChakravartiA., ErkkinenM.G., NestlerU., StuppR., MehtaM., AldapeK., GilbertM.R., BlackP.M., LoefflerJ.S.: Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res, 12: 4738–4746, 2006.
16.
Panet-RaymondV., SouhamiL., RobergeD., KavanP., ShakibniaL., MuanzaT., LambertC., LeblancR., Del MaestroR., GuiotM.C., ShenoudaG.Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys, 73: 473–478, 2009.
